A trial update dated September 11, 2026 reports on the CAlcium and VAsopressin Following Injury Early Resuscitation, or CAVALIER, trial. This study involves vasopressin, an approved compound, in the context of early resuscitation after injury. According to the update, the trial is registered under identifier NCT05958342 and is listed as Phase 2. The trial's current status is recruiting, meaning participants are still being enrolled as of this update. The event data does not include information on trial results, endpoints, or outcomes at this stage. No efficacy or safety findings have been reported as part of this update. The information provided reflects only the recruitment status and phase classification as recorded on the trial registry. Readers interested in the compound's broader background, including its approved regulatory status, can consult the vasopressin overview for additional context.
Vasopressin Phase 2 Trial CAVALIER Recruiting as of Sept 2026
See the full vasopressin overview
Source: https://clinicaltrials.gov/study/NCT05958342